About Amylin
Amylin is a company based in San Diego (United States) founded in 1987 was acquired by Bristol-Myers Squibb in June 2012. Amylin operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amylin Pharmaceuticals Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$100 M (USD), Post-IPO
Feb 22, 2000
- Investors
-
Employee Count
Not available
-
Acquired by
Bristol-Myers Squibb
(Jun 29, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Amylin
Investors in Amylin
Amylin has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis
|
Locked | Locked | Locked |
Investor details for Amylin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amylin
Investment portfolio details for Amylin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amylin
Detailed financials for Amylin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amylin Comparisons
Peer comparison for Amylin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amylin
Amylin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
Detailed competitors of Amylin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amylin
Complete news archive for Amylin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amylin
Amylin was founded in 1987 and raised its 1st funding round 13 years after it was founded.
Amylin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDAapproved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystroph. In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for 5.3 billion. In December 2013, Amylin was acquired by AstraZeneca.
Amylin's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Amylin has 1 investor. Key investors include Bristol-Myers Squibb.